CITIUS ONCOLOGY, INC. 8K

Citius Oncology, Inc. announced fiscal third quarter 2026 results and a business update showing growing LYMPHIR commercialization, new financing and loan funding, advancement of clinical combination studies, and the appointment of a new independent director, alongside continued operating losses.

On August 14, 2026, Citius Oncology, Inc. reported its fiscal third quarter 2026 financial results and provided a business update highlighting growing commercial momentum for its CTCL therapy LYMPHIR, including $7.1 million in revenue for the first nine months of fiscal 2026 (with $1.5 million in Q3), accelerating institutional demand (a 31% sequential increase in vials ordered and 44 institutions prescribing since launch), near-universal payer coverage, and a significant expansion of its commercial and medical affairs footprint to nationwide coverage. The Company also disclosed key financing developments, including approximately $9.7 million in net proceeds from warrant exercises and the funding of $10.0 million under the first tranche of a senior secured term loan facility of up to $25.0 million, as well as a cash balance of $16.6 million as of June 30, 2026. Operationally, Citius Oncology advanced investigator-initiated Phase 1 studies of LYMPHIR in combination regimens (with pembrolizumab in gynecologic cancers and as a pre-CAR-T therapy in high-risk DLBCL) that showed encouraging efficacy and tolerability data, and it appointed Jonathan Peri, Ph.D., J.D., as an independent director on August 10, 2026. Despite revenue growth and gross profit of $5.5 million year-to-date, the Company reported a net loss of $8.9 million in Q3 and $41.1 million for the nine months ended June 30, 2026, driven largely by higher general and administrative spending tied to commercialization and a previously recognized $19.7 million one-time CMO contract cancellation charge.

Filing Facts

CIK

1851484

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-090182

Alert Tier

6